Jefferies cuts Merck's remigromig sales forecast after eye-disease trial raises concerns

Jefferies cut its peak-sales forecast for Merck's experimental eye treatment remigromig by 60% after detailed trial results raised efficacy and safety concerns versus established rival Lucentis. Although remigromig met the statistical threshold for non-inferiority in diabetic macular oedema, its numerical improvement in patients' vision was smaller.

Analysis

The key risk is not statistical non-inferiority itself, but whether a merely comparable vision outcome can win physician adoption against a familiar incumbent when safety concerns are also in the discussion. That weakens the asset’s commercial differentiation: lower expected uptake, more price pressure, and potentially less leverage in payer negotiations. The spillover is favorable to established diabetic macular oedema options, including Lucentis and competing treatments, but this is not automatically a meaningful earnings catalyst for their owners without evidence of share gains.

Near term, MRK may remain sensitive to revisions in peak-sales estimates; the larger question is how much of the downgrade is already reflected in the stock, which cannot be established from the supplied information. Over 1–3 months, watch for full safety and efficacy data, dosing durability, subgroup results, and management’s development or launch plans. Over 6–18 months, the asset’s value depends on whether real-world persistence and switching overcome the trial’s weaker numerical efficacy signal. The impact is asset-specific; do not translate a lower peak-sales estimate directly into a consolidated MRK earnings revision without the company’s contribution and timing.

Contrarian angle: a non-inferiority result could still support a viable product if safety is manageable or convenience/dosing proves superior, but neither advantage is established here. The thesis is falsified by convincing detailed data showing a clean safety profile and a meaningful practical advantage, followed by credible uptake evidence. Conversely, a material safety signal or development retrenchment would make the downside more durable.

Key Decisions for Investors

• Keep MRK on a cautious/watch list rather than initiating a large directional position on one analyst forecast change; verify the full trial dataset and the asset’s contribution to MRK’s pipeline valuation first.
• For existing MRK exposure, review event risk and avoid adding ahead of further safety or development disclosures. A short-on-rallies thesis is conditional on the stock failing to recover after detailed data or management commentary; no price level is supplied to define an entry.
• Monitor Lucentis and other established DME options for evidence of incremental adoption, but do not treat the trial result alone as a buy signal for competing drug owners.
• Reassess if MRK provides evidence of superior dosing convenience, favorable safety, or differentiated subgroup efficacy; weaken the bearish view if those advantages are supported by data and later uptake.